

The 4th WFH Gene Therapy Round Table – Webinar Series 18 March, 10 June, 16 September 2021

Thursday March 18, 2021		
OPENING 9:00 AM – 9:15 AM		
WELCOME AND OBJECTIVES	Dr. Glenn Pierce, USA, Dr. John Pasi, UK	
9:15-9:45 AM		
GENE THERAPY UPDATE		
Safety, durability, variability, efficacy	Dr. Glenn Pierce, USA, Dr. John Pasi, UK	
SESSION 1: 9:45 AM – 11:25 AM		
GENE THERAPY AS A CHOICE: MAKING AN INFORMED DECISION		
Moderator: Dawn Rotellini, USA, Johnny Mahlangu, South Africa		
9:45-10:00 Nurse perspective on patient decision	Sara Garcia Barcenilla, Spain	
making		
10:00-10:15 Attributes to consider: The PAVING	Eline van Overbeeke, <i>Belgium</i>	
Study		
10:15-10:30 Exigency: why some people with	Simon Fletcher, UK	
haemophilia have no interest in gene therapy		
10:30-10:45 Gene therapy considerations in LIC	Bishesh Poudyal, Nepal	
10:45-10:55 Q&A and DISCUSSION		
10:55-11:25 Panel Discussion on decision making	Brian O'Mahony, Ireland, Luke Pembroke, UK,	
	Steven Scott, South Africa	

BREAK 11:25 - 11:35 AM

SESSION 2: 11:35 AM – 12:45 PM		
SMALL GROUP BREAK OUTS		
Moderators: John Pasi, UK		
11:35-11:40 Introduction to small group break-out	Donna Coffin, Canada	
11:40-12:10 Small group break out	1. Delivering balanced information	
	2. What does the evidence say?	
	3. Treatment related clinical considerations	
	4. Patient clinical profile	
	5. Patient preferences	
	6. Weighing the factors	
	7. Low resource setting	
12:10-12:45 Reporting back		
CLOSING 12:45 AM – 13:00 PM		
MARCH WEBINAR WRAP-UP	Dr. Glenn Pierce, USA, Dr. John Pasi, UK	



	00 AM – 9:10 AM	
WELCOME AN	ND OBJECTIVES	Dr. Glenn Pierce, USA
9:10-9:25 A	N	
GENE THERA	PY UPDATE	
Status update	on gene therapy clinical trials	Dr. John Pasi <i>, UK</i>
SESSION 1: 9	9:25 AM – 10:55 AM	
How should I	interpret emerging data?	
Moderator: O	ilenn Pierce	
9:25-9:40	Assay description	Dr. Radoslaw Kaczmarek, USA
9:40-9:55	What do the assays mean?	Dr. David Lillicrap, Canada
9:55-10:05	Discussion	
10:05-11:00	What do the numbers mean? Panel & discussion	Dr. John Pasi, UK, Dr. Courtney
	Does the average patient exist? What numbers does	Thornburg, USA, Dr. Shannon
	each patient need to make an informed decision?	Jackson, Canada, Thomas Sannié,
	How will I define whether gene therapy is working	France, Declan Noone, Ireland,
	for me?	Mark Skinner, USA

SESSION 2: 11:10 AM – 12:40 PM				
Looking into the crystal ball				
Moderator: Johnny Mahlangu				
11:10-11:25	Organization & delivery of care – USA	Dr. Steven Pipe, USA		
11:25-11:40	Organization & delivery of care – Europe	Dr. Wolfgang Miesbach, Germany		
11:40-11:55	Organization & delivery of care – Brazil	Dr. Margareth Ozelo, Brazil		
11:55-12:10	Discussion			
12:10-12:25	Gene editing & hemophilia: possible or not?	Dr. Robert Peters, USA		
12:25-12:40	Discussion			
CLOSING 12:40 PM – 12:55 PM				
WEBINAR W	RAP-UP	Dr. Glenn Pierce <i>, USA</i> , Dr. John Pasi, <i>UK</i>		
		rasi, un		

Thank you to our generous sponsors:



BOMARIN

CSL Behring Biotherapies for Life[™]













